SearchOur group seeks to understand the biological basis of schizophrenia and its treatment via a wide range of approaches.
Focuses of our work include impulsivity, suicidality, aggression, perception, and negative symptoms, alcohol use disorder, social cognition, as well as cognitive and social remediation approaches, psychopharmacological treatment studies, and examination of pharmacogenetic and immunological biomarkers (including those for COVID-19) relevant to the disorder.
These are evaluated using neuropsychological testing, psychometric evaluations, neuroimaging, EEG, serum level quantitation, and medical record reviews.
Work is supported by grants from The American Foundation for Suicide Prevention (Hoptman) and The National Institute of Mental Health (Butler, Clelland, Iosifescu, Krakowski).